Evidence map›Paper›PMID 23628166›Full record

ReviewCurrent opinion in immunology2013

Human immune responses and potential for vaccine assessment in humanized mice.

Ramesh Akkina

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 63 citations in OpenAlex.

  1. Vaccinology: Getting our modernization act together.The Journal of experimental medicine · 2025
    Article
  2. Review
  3. Humanized mouse model for vaccine evaluation: an overview.Clinical and experimental vaccine research · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Dissemination ofFrontiers in immunology · 2018
    Article
  17. Review
  18. Review
  19. Article
  20. Humanized Mouse Models ofFrontiers in immunology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ramesh AkkinaDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA. akkina@colostate.edu
Colorado State University · US

Funding

Vascular stabilization as a broad theraprutic platform for biodefenseU54AI065357 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI BELISLE, JOHN T · 2005 to 2013
$77.5M
Targeted Delivery Vechicles for OligonucleotidesP01AI099783 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI AKKINA, RAMESH · 2012 to 2016
$7.4M
Expression of anti-HIV siRNA in Blood CellsR01HL074704 · NHLBI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI BURNETT, JOHN CORY, ROSSI, JOHN JOSEPH · 2003 to 2015
$5.0M
Modeling Next Generation HIV PrEP in Humanized MiceR01AI100845 · NIAID · COLORADO STATE UNIVERSITY · PI AKKINA, RAMESH · 2012 to 2014
$2.0M
Humanized Rag2-/-gammac-/-mice for HIV infection and gene therapyR01AI073255 · NIAID · COLORADO STATE UNIVERSITY · PI AKKINA, RAMESH · 2007 to 2011
$1.8M
Efficacy Testing of HIV-Specific Microbicides in Humanized MiceR56AI095101 · NIAID · COLORADO STATE UNIVERSITY · PI AKKINA, RAMESH · 2012 to 2012
$445k
Human embryonic stem (hES) cells for hematopoietic and HIV/AIDS therapiesR21HL094257 · NHLBI · COLORADO STATE UNIVERSITY · PI AKKINA, RAMESH · 2008 to 2009
$404k
NHLBI NIH HHS HL074704NHLBI NIH HHS HL94257NHLBI NIH HHS R01 HL074704NHLBI NIH HHS R21 HL094257NIAID NIH HHS AI073255NIAID NIH HHS AI095101NIAID NIH HHS AI100845NIAID NIH HHS P01 AI099783NIAID NIH HHS P01AI099783NIAID NIH HHS R01 AI073255NIAID NIH HHS R01 AI100845NIAID NIH HHS R56 AI095101NIAID NIH HHS U54 AI065357NIAID NIH HHS U54AI065357
6 · The paper itself

Abstract

The new humanized mouse models with a transplanted human immune system have a capacity for de novo multilineage human hematopoiesis and generate T cells, B cells, macrophages, dendritic cells and NK cells. Of the two current leading humanized mouse models, the hu-HSC model is created by human hematopoietic stem cell (HSC) engraftment whereas the BLT mouse model is prepared by co-transplantation of human fetal liver, thymus and HSC. Humoral and cellular immune responses are seen in both models after immunization with antigens or infection with hematotropic pathogens such as EBV, HIV-1 and dengue viruses. While consistent antigen specific IgM production is seen, IgG responses were found to be generally feeble which is attributed to inefficient immunoglobulin class switching. BLT mice permit human HLA restricted T cell responses due to the autologous human thymus contributing to T cell maturation. Use of HLA Class I and II transgenic hu-HSC mice recently demonstrated that the HLA restriction deficiency could be overcome in this model. However, the overall vigor of the immune responses needs further improvement in both the models to approach that of the human. Towards this goal, supplementation with human cytokines and growth factors by transgenesis to improve human cell reconstitution and their homeostatic maintenance are beginning to yield improved mouse strains to create more robust human immune competent mice for immunoprophylaxis studies.

Indexed as

AnimalsHLA AntigensHumansImmunity, CellularImmunologic Deficiency SyndromesMiceVaccinesHLA AntigensVaccines

Identifiers

PMID23628166
PMCPMC3894824
OpenAlexW2126612430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.